The Surging Popularity of GLP-1s By 2024, approximately 4% of Americans were taking a GLP-1 receptor agonist for weight loss, obesity, or type 2 diabetesa staggering 600% increase since 2018
The unusual origin story captured public imagination, but also initially caused some wariness convincing people to inject a reptile-derived compound required education
Contraindications may include active cancer-related conditions, a history of pancreatitis, pregnancy, breastfeeding, and individual intolerance to the components
Lab work is included with all plans rather than billed separately, which is uncommon at this price point
Visit www.FunctionalMedicineUniversity.com for more information on our training in functional medicine
A year after the study began, the COVID-19 pandemic struck